Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

Xiaoping Zhang, Jacob P. Lalezari, Andrew David Badley, Albert Dorr, Stanley J. Kolis, Tosca Kinchelow, Indravadan H. Patel

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Introduction Enfuvirtide is the first drug to block human immunodeficiency virus type 1 (HIV-1) glycoprotein 41-mediated viral fusion to host cells. This study investigated whether enfuvirtide can influence the activities of cytochrome P450 (CYP) enzymes in HIV-1-infected patients. Methods An open-label, 1-sequence crossover study was conducted in 12 HIV-1-infected adults, by use of a 5-drug cocktail consisting of caffeine, chlorzoxazone, dapsone, debrisoquin (INN, debrisoquine), and mephenytoin to assess the activities of CYP1A2, CYP2E1, CYP3A4, CYP2D6, and CYP2C19, respectively. Dapsone was used to assess N-acetyltransferase activity. Patients received a single dose of the cocktail alone on day -15 and another together with enfuvirtide on day 6. Enfuvirtide (90 mg subcutaneously) was administered twice daily on days 1 to 7. Phenotypic index parameters were estimated and analyzed by ANOVA with factors subject and day (-15 and 6). Results The phenotypic index parameters, with and without enfuvirtide, for CYP3A4 (0.33 versus 0.34; 90% confidence interval [CI] for ratio of least squares means, 0.88-1.09), CYP2D6 (0.72 versus 0.71; 90% CI, 0.97-1.06), and N-acetyltransferase (0.35 versus 0.39; 90% CI, 0.82-0.98) were bioequivalent. The phenotypic index parameters, with and without enfuvirtide, for CYP1A2 (0.76 versus 0.81; 90% CI, 0.71-1.17), CYP2E1 (1.3 versus 1.2; 90% CI, 0.87-1.29), and CYP2C19 (93 versus 81.8; 90% CI, 0.98-1.28) were not bioequivalent but were not substantially different. Conclusions Enfuvirtide had no clinically important effect on the metabolism of probe drugs mediated by CYP3A4, CYP2D6, or N-acetyltransferase and had little effect on the metabolism of drugs mediated by CYP1A2, CYP2E1, or CYP2C19. The potential for interactions between enfuvirtide and concomitantly administered drugs metabolized by the CYP enzymes tested in this study is low.

Original languageEnglish (US)
Pages (from-to)558-568
Number of pages11
JournalClinical Pharmacology and Therapeutics
Volume75
Issue number6
DOIs
StatePublished - Jun 2004

Fingerprint

Drug Interactions
HIV-1
Confidence Intervals
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP2E1
Cytochrome P-450 CYP1A2
Pharmaceutical Preparations
Cytochrome P-450 CYP2D6
Cytochrome P-450 Enzyme System
Acetyltransferases
Debrisoquin
Dapsone
Chlorzoxazone
Mephenytoin
enfuvirtide
Caffeine
Least-Squares Analysis
Cross-Over Studies
Analysis of Variance
Cytochrome P-450 CYP2C19

ASJC Scopus subject areas

  • Pharmacology

Cite this

Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. / Zhang, Xiaoping; Lalezari, Jacob P.; Badley, Andrew David; Dorr, Albert; Kolis, Stanley J.; Kinchelow, Tosca; Patel, Indravadan H.

In: Clinical Pharmacology and Therapeutics, Vol. 75, No. 6, 06.2004, p. 558-568.

Research output: Contribution to journalArticle

Zhang, Xiaoping ; Lalezari, Jacob P. ; Badley, Andrew David ; Dorr, Albert ; Kolis, Stanley J. ; Kinchelow, Tosca ; Patel, Indravadan H. / Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. In: Clinical Pharmacology and Therapeutics. 2004 ; Vol. 75, No. 6. pp. 558-568.
@article{ee9b1f98203a438e866561a0f11f428d,
title = "Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients",
abstract = "Introduction Enfuvirtide is the first drug to block human immunodeficiency virus type 1 (HIV-1) glycoprotein 41-mediated viral fusion to host cells. This study investigated whether enfuvirtide can influence the activities of cytochrome P450 (CYP) enzymes in HIV-1-infected patients. Methods An open-label, 1-sequence crossover study was conducted in 12 HIV-1-infected adults, by use of a 5-drug cocktail consisting of caffeine, chlorzoxazone, dapsone, debrisoquin (INN, debrisoquine), and mephenytoin to assess the activities of CYP1A2, CYP2E1, CYP3A4, CYP2D6, and CYP2C19, respectively. Dapsone was used to assess N-acetyltransferase activity. Patients received a single dose of the cocktail alone on day -15 and another together with enfuvirtide on day 6. Enfuvirtide (90 mg subcutaneously) was administered twice daily on days 1 to 7. Phenotypic index parameters were estimated and analyzed by ANOVA with factors subject and day (-15 and 6). Results The phenotypic index parameters, with and without enfuvirtide, for CYP3A4 (0.33 versus 0.34; 90{\%} confidence interval [CI] for ratio of least squares means, 0.88-1.09), CYP2D6 (0.72 versus 0.71; 90{\%} CI, 0.97-1.06), and N-acetyltransferase (0.35 versus 0.39; 90{\%} CI, 0.82-0.98) were bioequivalent. The phenotypic index parameters, with and without enfuvirtide, for CYP1A2 (0.76 versus 0.81; 90{\%} CI, 0.71-1.17), CYP2E1 (1.3 versus 1.2; 90{\%} CI, 0.87-1.29), and CYP2C19 (93 versus 81.8; 90{\%} CI, 0.98-1.28) were not bioequivalent but were not substantially different. Conclusions Enfuvirtide had no clinically important effect on the metabolism of probe drugs mediated by CYP3A4, CYP2D6, or N-acetyltransferase and had little effect on the metabolism of drugs mediated by CYP1A2, CYP2E1, or CYP2C19. The potential for interactions between enfuvirtide and concomitantly administered drugs metabolized by the CYP enzymes tested in this study is low.",
author = "Xiaoping Zhang and Lalezari, {Jacob P.} and Badley, {Andrew David} and Albert Dorr and Kolis, {Stanley J.} and Tosca Kinchelow and Patel, {Indravadan H.}",
year = "2004",
month = "6",
doi = "10.1016/j.clpt.2004.02.003",
language = "English (US)",
volume = "75",
pages = "558--568",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

AU - Zhang, Xiaoping

AU - Lalezari, Jacob P.

AU - Badley, Andrew David

AU - Dorr, Albert

AU - Kolis, Stanley J.

AU - Kinchelow, Tosca

AU - Patel, Indravadan H.

PY - 2004/6

Y1 - 2004/6

N2 - Introduction Enfuvirtide is the first drug to block human immunodeficiency virus type 1 (HIV-1) glycoprotein 41-mediated viral fusion to host cells. This study investigated whether enfuvirtide can influence the activities of cytochrome P450 (CYP) enzymes in HIV-1-infected patients. Methods An open-label, 1-sequence crossover study was conducted in 12 HIV-1-infected adults, by use of a 5-drug cocktail consisting of caffeine, chlorzoxazone, dapsone, debrisoquin (INN, debrisoquine), and mephenytoin to assess the activities of CYP1A2, CYP2E1, CYP3A4, CYP2D6, and CYP2C19, respectively. Dapsone was used to assess N-acetyltransferase activity. Patients received a single dose of the cocktail alone on day -15 and another together with enfuvirtide on day 6. Enfuvirtide (90 mg subcutaneously) was administered twice daily on days 1 to 7. Phenotypic index parameters were estimated and analyzed by ANOVA with factors subject and day (-15 and 6). Results The phenotypic index parameters, with and without enfuvirtide, for CYP3A4 (0.33 versus 0.34; 90% confidence interval [CI] for ratio of least squares means, 0.88-1.09), CYP2D6 (0.72 versus 0.71; 90% CI, 0.97-1.06), and N-acetyltransferase (0.35 versus 0.39; 90% CI, 0.82-0.98) were bioequivalent. The phenotypic index parameters, with and without enfuvirtide, for CYP1A2 (0.76 versus 0.81; 90% CI, 0.71-1.17), CYP2E1 (1.3 versus 1.2; 90% CI, 0.87-1.29), and CYP2C19 (93 versus 81.8; 90% CI, 0.98-1.28) were not bioequivalent but were not substantially different. Conclusions Enfuvirtide had no clinically important effect on the metabolism of probe drugs mediated by CYP3A4, CYP2D6, or N-acetyltransferase and had little effect on the metabolism of drugs mediated by CYP1A2, CYP2E1, or CYP2C19. The potential for interactions between enfuvirtide and concomitantly administered drugs metabolized by the CYP enzymes tested in this study is low.

AB - Introduction Enfuvirtide is the first drug to block human immunodeficiency virus type 1 (HIV-1) glycoprotein 41-mediated viral fusion to host cells. This study investigated whether enfuvirtide can influence the activities of cytochrome P450 (CYP) enzymes in HIV-1-infected patients. Methods An open-label, 1-sequence crossover study was conducted in 12 HIV-1-infected adults, by use of a 5-drug cocktail consisting of caffeine, chlorzoxazone, dapsone, debrisoquin (INN, debrisoquine), and mephenytoin to assess the activities of CYP1A2, CYP2E1, CYP3A4, CYP2D6, and CYP2C19, respectively. Dapsone was used to assess N-acetyltransferase activity. Patients received a single dose of the cocktail alone on day -15 and another together with enfuvirtide on day 6. Enfuvirtide (90 mg subcutaneously) was administered twice daily on days 1 to 7. Phenotypic index parameters were estimated and analyzed by ANOVA with factors subject and day (-15 and 6). Results The phenotypic index parameters, with and without enfuvirtide, for CYP3A4 (0.33 versus 0.34; 90% confidence interval [CI] for ratio of least squares means, 0.88-1.09), CYP2D6 (0.72 versus 0.71; 90% CI, 0.97-1.06), and N-acetyltransferase (0.35 versus 0.39; 90% CI, 0.82-0.98) were bioequivalent. The phenotypic index parameters, with and without enfuvirtide, for CYP1A2 (0.76 versus 0.81; 90% CI, 0.71-1.17), CYP2E1 (1.3 versus 1.2; 90% CI, 0.87-1.29), and CYP2C19 (93 versus 81.8; 90% CI, 0.98-1.28) were not bioequivalent but were not substantially different. Conclusions Enfuvirtide had no clinically important effect on the metabolism of probe drugs mediated by CYP3A4, CYP2D6, or N-acetyltransferase and had little effect on the metabolism of drugs mediated by CYP1A2, CYP2E1, or CYP2C19. The potential for interactions between enfuvirtide and concomitantly administered drugs metabolized by the CYP enzymes tested in this study is low.

UR - http://www.scopus.com/inward/record.url?scp=2942594069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942594069&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2004.02.003

DO - 10.1016/j.clpt.2004.02.003

M3 - Article

C2 - 15179410

AN - SCOPUS:2942594069

VL - 75

SP - 558

EP - 568

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -